In the NSCLC population, it is likely that EGFR is overrepresented given it is standard of care to obtain ctDNA at the time of progression to assess for resistance alterations, which is not routinely done with other genotypes. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.